JP2015527875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527875A5 JP2015527875A5 JP2015516469A JP2015516469A JP2015527875A5 JP 2015527875 A5 JP2015527875 A5 JP 2015527875A5 JP 2015516469 A JP2015516469 A JP 2015516469A JP 2015516469 A JP2015516469 A JP 2015516469A JP 2015527875 A5 JP2015527875 A5 JP 2015527875A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide sequence
- st6galnac3
- c1orf114
- hapln3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 164
- 239000002773 nucleotide Substances 0.000 claims 163
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 101
- 102100031971 Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 Human genes 0.000 claims 86
- 101000703721 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 Proteins 0.000 claims 86
- 101000772632 Homo sapiens Coiled-coil domain-containing protein 181 Proteins 0.000 claims 85
- 102100030507 Coiled-coil domain-containing protein 181 Human genes 0.000 claims 83
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 83
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 83
- 101001078431 Homo sapiens Hyaluronan and proteoglycan link protein 3 Proteins 0.000 claims 83
- 102100025260 Hyaluronan and proteoglycan link protein 3 Human genes 0.000 claims 83
- 101000785611 Homo sapiens Zinc finger protein 660 Proteins 0.000 claims 81
- 102100026454 Zinc finger protein 660 Human genes 0.000 claims 81
- 238000007069 methylation reaction Methods 0.000 claims 63
- 230000011987 methylation Effects 0.000 claims 57
- 102100036826 Aldehyde oxidase Human genes 0.000 claims 51
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 claims 51
- 206010060862 Prostate cancer Diseases 0.000 claims 50
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 50
- 238000000034 method Methods 0.000 claims 46
- 230000000295 complement effect Effects 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 34
- 239000000523 sample Substances 0.000 claims 32
- 238000013518 transcription Methods 0.000 claims 22
- 230000035897 transcription Effects 0.000 claims 22
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 239000013068 control sample Substances 0.000 claims 14
- 239000000090 biomarker Substances 0.000 claims 13
- 230000002103 transcriptional effect Effects 0.000 claims 13
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 12
- 238000004393 prognosis Methods 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 238000011471 prostatectomy Methods 0.000 claims 7
- 230000005855 radiation Effects 0.000 claims 7
- 206010061818 Disease progression Diseases 0.000 claims 6
- 230000000875 corresponding effect Effects 0.000 claims 6
- 230000005750 disease progression Effects 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 230000005713 exacerbation Effects 0.000 claims 5
- 238000002203 pretreatment Methods 0.000 claims 5
- 238000009098 adjuvant therapy Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000002596 correlated effect Effects 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 101150061183 AOX1 gene Proteins 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 2
- 101150022345 GAS6 gene Proteins 0.000 claims 2
- 101100451399 Homo sapiens HAPLN3 gene Proteins 0.000 claims 2
- 101150073902 ZNF660 gene Proteins 0.000 claims 2
- 230000016571 aggressive behavior Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 206010063659 Aversion Diseases 0.000 claims 1
- 206010061819 Disease recurrence Diseases 0.000 claims 1
- 102000017705 GABRE Human genes 0.000 claims 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims 1
- 101001073581 Homo sapiens Gamma-aminobutyric acid receptor subunit epsilon Proteins 0.000 claims 1
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims 1
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 claims 1
- 101000976579 Homo sapiens Zinc finger protein 132 Proteins 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091033411 PCA3 Proteins 0.000 claims 1
- 102100036090 Pituitary homeobox 2 Human genes 0.000 claims 1
- 108091006775 SLC18A2 Proteins 0.000 claims 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 claims 1
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 1
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 1
- 102100023572 Zinc finger protein 132 Human genes 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 239000012502 diagnostic product Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000002991 immunohistochemical analysis Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270326 | 2012-06-14 | ||
| DKPA201270326 | 2012-06-14 | ||
| PCT/DK2013/050196 WO2013185779A2 (en) | 2012-06-14 | 2013-06-14 | Biomarkers for prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527875A JP2015527875A (ja) | 2015-09-24 |
| JP2015527875A5 true JP2015527875A5 (enExample) | 2016-07-07 |
| JP6242388B2 JP6242388B2 (ja) | 2017-12-06 |
Family
ID=48740787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516469A Active JP6242388B2 (ja) | 2012-06-14 | 2013-06-14 | 前立腺ガンのバイオマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10106854B2 (enExample) |
| EP (1) | EP2861759B1 (enExample) |
| JP (1) | JP6242388B2 (enExample) |
| AU (1) | AU2013275761B2 (enExample) |
| CA (1) | CA2876252A1 (enExample) |
| WO (1) | WO2013185779A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3037545A1 (en) * | 2014-12-23 | 2016-06-29 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | A DNA-methylation test for prostate cancer |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN106480169B (zh) * | 2015-09-01 | 2019-10-08 | 杨小丽 | 人aqp10和sox17基因甲基化位点的检测和应用 |
| CA3054836A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Detecting prostate cancer |
| GB201816820D0 (en) | 2018-10-16 | 2018-11-28 | Univ York | Diagnostic method |
| WO2020099277A1 (en) | 2018-11-13 | 2020-05-22 | Bracco Imaging Spa | Gene signatures for the prediction of prostate cancer recurrence |
| CN109468381B (zh) * | 2018-11-19 | 2022-11-25 | 兰州市第一人民医院 | 用于宫颈癌筛查的甲基化位点及其检测引物 |
| EP3999662A1 (en) * | 2019-07-19 | 2022-05-25 | Vilnius University | Characterization of prostate cancer using dna methylation assay system |
| CN113122636A (zh) * | 2020-01-14 | 2021-07-16 | 上海鹍远生物技术有限公司 | 检测dna甲基化的试剂及用途 |
| US20230167506A1 (en) * | 2020-05-04 | 2023-06-01 | Mayo Foundation For Medical Education And Research | Detecting pancreatic neuroendocrine tumors |
| WO2021226110A1 (en) * | 2020-05-05 | 2021-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free dna biomarkers and their use in diagnosis, monitoring response to therapy, and selection of therapy for prostate cancer |
| CN118685523B (zh) * | 2024-08-26 | 2024-11-15 | 湖南宏雅基因技术有限公司 | 一种用于前列腺癌检测的生物标志物组合、引物探针组合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6605432B1 (en) | 1999-02-05 | 2003-08-12 | Curators Of The University Of Missouri | High-throughput methods for detecting DNA methylation |
| DE60232059D1 (de) * | 2001-03-01 | 2009-06-04 | Epigenomics Ag | Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene |
| WO2008143896A1 (en) * | 2007-05-14 | 2008-11-27 | The Johns Hopkins University | Methylation markers for prostate cancer and methods of use |
| CN102308003A (zh) * | 2008-08-05 | 2012-01-04 | 维里德克斯有限责任公司 | 前列腺癌甲基化分析法 |
| EP3524697B1 (en) * | 2009-01-07 | 2024-10-02 | Myriad Genetics, Inc. | Cancer biomarkers |
| US20100303795A1 (en) | 2009-05-27 | 2010-12-02 | Soerensen Karina Dalsgaard | Marker of prostate cancer |
| WO2011027310A1 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| WO2011037936A2 (en) * | 2009-09-24 | 2011-03-31 | Oregon Health & Science University | Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer |
| WO2011044902A1 (en) | 2009-10-13 | 2011-04-21 | Aarhus Universitet | Tff3 hypomethylation as a novel biomarker for prostate cancer |
| WO2011112845A2 (en) * | 2010-03-11 | 2011-09-15 | Board Of Regents, The University Of Texas System | Methods and compositions related to a multi-methylation assay to predict patient outcome |
| US20140094380A1 (en) * | 2011-04-04 | 2014-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methylation Biomarkers for Diagnosis of Prostate Cancer |
-
2013
- 2013-06-14 EP EP13732819.1A patent/EP2861759B1/en active Active
- 2013-06-14 US US14/407,541 patent/US10106854B2/en active Active
- 2013-06-14 CA CA2876252A patent/CA2876252A1/en active Pending
- 2013-06-14 WO PCT/DK2013/050196 patent/WO2013185779A2/en not_active Ceased
- 2013-06-14 AU AU2013275761A patent/AU2013275761B2/en active Active
- 2013-06-14 JP JP2015516469A patent/JP6242388B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527875A5 (enExample) | ||
| Zhang et al. | Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling | |
| Yu et al. | Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma | |
| AU2011302004B2 (en) | Molecular diagnostic test for cancer | |
| JP6449779B2 (ja) | 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価 | |
| Lieb et al. | Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients | |
| JP2016536001A (ja) | 肺がんのための分子診断試験 | |
| CN114594259B (zh) | 一种新型的用于结直肠癌预后预测和诊断的模型及其应用 | |
| Liu et al. | Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer | |
| JP2016519926A (ja) | 複数の細胞内シグナル伝達経路活性を用いた治療反応の医学的予後及び予測 | |
| JP2011500071A (ja) | 遺伝子に基づくアルゴリズム的ガン予後及び患者の臨床結果 | |
| WO2015033172A1 (en) | Molecular diagnostic test for oesophageal cancer | |
| CN101173313B (zh) | 乳腺癌转移和预后分子分型基因群及其基因芯片制备和应用方法 | |
| CN112391468A (zh) | 脑癌检测 | |
| CN108728534A (zh) | 4-LncRNA分子标签用于肝癌预后评估的试剂盒 | |
| CN112063714A (zh) | 一种与结直肠癌相关的miRNA及其应用 | |
| WO2014111561A1 (en) | Serum mirna-142-3p as prognostic cancer marker | |
| CN110592223B (zh) | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 | |
| CN113736879A (zh) | 用于小细胞肺癌患者预后的系统及其应用 | |
| CN113826166A (zh) | 评估气道上皮细胞中的多信号传导途径活性评分以预测气道上皮异常和气道癌风险 | |
| US20240093306A1 (en) | Micro rna liver cancer markers and uses thereof | |
| Fan et al. | Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy | |
| JP7663987B2 (ja) | 非小細胞肺癌のモニタリング方法およびキット | |
| CN115094059B (zh) | 生物标志物在制备辅助诊断癌症的试剂中的应用 | |
| Ding et al. | Serum long non-coding RNA signatures serve as novel noninvasive biomarkers for diagnosis and prognosis of gastric cancer |